AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 92 min read$QGEN

QGEN Maintained by UBS -- Price Target Lowered to $47.00

UBS maintained a Neutral rating on Qiagen (QGEN) but lowered its price target to $47.00 from $52.00. GuruFocus values QGEN at $49.37, suggesting it is 14.0% undervalued. The company's P/E (TTM) is 21.47x, below its 5-year median. Analysts have mixed views on QGEN, with some seeing potential for value appreciation.

Original reporting
gurufocus.com
Published Sep 9, 2026, 7:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 2:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$QGEN
Bearish
medium confidence
Mentioned
$QGEN
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$QGENBearishLow
01

Why it matters

Analyst target reduction may prompt short sellers, but valuation metrics still suggest upside.

02

Market read

Analyst rating change provides modest trading insight for biotech-focused investors.

03

What to watch

Potential upside from upcoming product launches not reflected in the target.

Relevance 6/10Novelty 6/10Timing: Sep 9 2026 (same day release)

Background

Qiagen is a leading provider of sample and assay technologies with a market cap of ~$8.8B.

Company-level read

Ticker impact

$QGENBearishMedium confidence
Context

UBS lowered its price target for Qiagen to $47.00, a new analyst rating change disclosed on Sep 9, 2026.

Expected impact

Modest price decline expected in the near term.

Evidence & confidence

Analyst target cut reflects sector uncertainties; no new fundamental data released.

Market effects

Sector

Highlights caution in the medical diagnostics sector, may affect peers.

Regional

Limited to US and European biotech investors.

Global

Minor, as Qiagen is a mid-cap biotech with niche exposure.

Counterpoint

What could challenge this read

Despite the target cut, the stock remains undervalued at $42.47, offering a buying opportunity.

Key entities

  • Company
    Qiagen NV

    Life sciences and molecular diagnostics firm.

  • Analyst
    UBS

    Maintained Neutral rating and lowered price target.

Read at source← All news

Related articles

SEP 28
$QGENMedAI 8/10

FDA Clears Qiagen QIAstat

Qiagen's QIAstat-Dx BCID GN Plus AMR Panel, cleared by the FDA, detects 13 gram-negative bacteria and 18 antibiotic resistance markers in about an hour. The test complements the previously cleared gram-positive and fungal panel, offering rapid bloodstream infection identification. Qiagen aims to support timely treatment decisions and address antibiotic resistance, with the QIAstat-Dx system available in over 100 countries.

clpmag.com2 min
SEP 17
$QGENMedAI 8/10

QIAGEN (QGEN) Rolls Out QIAsymphony Connect Following Q2 Outperformance

QIAGEN (QGEN) launched QIAsymphony Connect, an automated platform for clinical nucleic acid extraction. The company reported Q2 net sales of $535M, beating guidance, with growth pillars like Sample technologies and QIAcuity driving performance. However, some segments faced challenges, and the full-year outlook was reaffirmed. The stock trades at a forward P/E of 13.16, with mixed institutional interest.

insidermonkey.com3 min
SEP 5
$QGENMedAI 8/10

QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest

Qiagen (QGEN) shares rose over 10% after reports of potential takeover interest from private equity firms, including EQT, Advent, and KKR, with offers around $50 per share. This exceeds the stock's $44.46 analyst consensus price target. The company is working with Moelis & Co. and Goldman Sachs on strategic options. QGEN develops molecular testing technologies and has seen increased retail investor bullish sentiment.

stocktwits.com2 min